J. Griffin

José A Fernández, K. Salmela, L. Lindgren, 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Interaction of type 1 plasminogen activator inhibitor with the enzymes of the contact activation system.

J. Griffin, F. España, D. Loskutoff, 1989, The Journal of biological chemistry.

Molecular assembly in the contact phase of the Hageman factor system.

J. Griffin, C. Cochrane, 1979, The American journal of medicine.

Binding Site for Blood Coagulation Factor Xa Involving Residues 311–325 in Factor Va*

J. Griffin, T. Hackeng, A. Gale, 1998, The Journal of Biological Chemistry.

Prothrombin Residues 473–487 Contribute to Factor Va Binding in the Prothrombinase Complex*

José A Fernández, J. Griffin, R. Mesters, 2004, Journal of Biological Chemistry.

Factor Va Residues 311–325 Represent an Activated Protein C Binding Region*

J. Griffin, A. Gale, S. Yegneswaran, 2007, Journal of Biological Chemistry.

Specific DNA cleavage mediated by manganese complex [SalenMn(III)]+

J. Griffin, D. Gravert, 1993 .

Purification and characterization of plasma protein C inhibitor.

J. Griffin, F. España, M Berrettini, 1989, Thrombosis research.

A comparison of the abilities of plasma kallikrein, beta-Factor XIIa, Factor XIa and urokinase to activate plasminogen.

J. Griffin, L. Miles, J. Greengard, 1983, Thrombosis research.

Anti-Inflammatory, Antithrombotic, and Neuroprotective Effects of Activated Protein C in a Murine Model of Focal Ischemic Stroke

Berislav V. Zlokovic, John H. Griffin, José A Fernández, 2001, Circulation.

The Thrombin-sensitive Region of Protein S Mediates Phospholipid-dependent Interaction with Factor Xa*

J. Griffin, P. Dawson, T. Hackeng, 2008, Journal of Biological Chemistry.

Protein S binds to and inhibits factor Xa.

José A Fernández, J. Griffin, J. A. Fernandez, 1994, Proceedings of the National Academy of Sciences of the United States of America.

Binding of protein S to factor Va associated with inhibition of prothrombinase that is independent of activated protein C.

J. Griffin, J. Rosing, R. Mesters, 1993, The Journal of biological chemistry.

Plasma protein S deficiency in familial thrombotic disease.

J. Griffin, H. Schwarz, P. Hopmeier, 1984, Blood.

Cardiopulmonary bypass and activation of antithrombotic plasma protein C.

José A Fernández, J. Griffin, J. A. Fernandez, 1999, The Journal of thoracic and cardiovascular surgery.

Determination of functional and antigenic protein C inhibitor and its complexes with activated protein C in plasma by ELISA's.

J. Griffin, F. España, J H Griffin, 1989, Thrombosis research.

Protein-protein interactions in contact activation of blood coagulation. Binding of high molecular weight kininogen and the 5-(iodoacetamido) fluorescein-labeled kininogen light chain to prekallikrein, kallikrein, and the separated kallikrein heavy and light chains.

J. Griffin, P. E. Bock, J. Shore, 1985, The Journal of biological chemistry.

Dextran sulfate-dependent fibrinolysis in whole human plasma.

J. Griffin, L. Miles, Z. Rothschild, 1983, The Journal of laboratory and clinical medicine.

Human Prekallikrein (Plasminogen Proactivator): Purification, Characterization and Activation by Activated Factor XII

J. Griffin, B. Bouma, 1977, Thrombosis and Haemostasis.

Inactivation of purified human alpha 2-antiplasmin and purified human C1 inhibitor by synthetic fibrinolytic agents.

J. Griffin, M. Verlander, L. Miles, 1981, Blood.

Deficiency of factor XII-dependent plasminogen proactivator in prekallikrein-deficient plasma.

J. Griffin, B. Bouma, 1978, The Journal of laboratory and clinical medicine.

Human blood coagulation factor XI. Purification, properties, and mechanism of activation by activated factor XII.

J. Griffin, B N Bouma, J H Griffin, 1977, The Journal of biological chemistry.

inhibitor by synthetic fibrinolytic agents Inactivation of purified human alpha 2-antiplasmin and purified human C1

J. Griffin, L. Miles, A. J. Kleiss, 2013 .

STUDIES OF BOVINE NEUROPHYSIN‐NEUROHYPOPHYSEAL HORMONE INTERACTIONS

J. Griffin, J. S. Cohen, M. Camier, 1975, Annals of the New York Academy of Sciences.

Interaction of S-protein of complement with thrombin and antithrombin III during coagulation. Protection of thrombin by S-protein from antithrombin III inactivation.

B. Dahlbäck, J. Griffin, E. Podack, 1986, The Journal of biological chemistry.

127 Plasminogen activator inhibitor 3 (PAI-3, protein C inhibitor): Purification, characterization and specificity

J. Griffin, B. Binder, M. Geiger, 1988 .

126 Complex formation between urokinase (uPA) and plasma protein C inhibitor (PCI) in vivo

K. Huber, J. Griffin, B. Binder, 1988 .

and In Vivo

K. Huber, J. Griffin, B. Binder, 2017 .

Complex Formation Between Urokinase and Plasma Protein C Inhibitor In Vitro

K. Huber, J. Griffin, B. Binder, 2005 .

Complex formation between urokinase and plasma protein C inhibitor in vitro and in vivo.

K. Huber, J. Griffin, B. Binder, 1989, Blood.

AUTOACTIVATION OF HUMAN PLASMA PREKALLIKREIN

J Rosing, B. Lämmle, J. Griffin, 1987, Thrombosis and Haemostasis.

Contributions of human platelets to the proteolytic activation of blood coagulation factors XII and XI.

J. Griffin, P. Walsh, J H Griffin, 1981, Blood.

Nonenzymatic anticoagulant activity of the mutant serine protease Ser360Ala‐activated protein C mediated by factor Va

J. Griffin, A. Gale, M. J. Heeb, 1997, Protein science : a publication of the Protein Society.

Identification of Distinct Sequences in Human Blood Coagulation Factor Xa and Prothrombin Essential for Substrate and Cofactor Recognition in the Prothrombinase Complex*

J. Griffin, R. Mesters, S. Yegneswaran, 2003, Journal of Biological Chemistry.

Low total protein S antigen but high protein S activity due to decreased C4b-binding protein in neonates.

J. Griffin, H. Schwarz, H. Watzke, 1988, Blood.

Models of the serine protease domain of the human antithrombotic plasma factor activated protein C and its zymogen

J. Griffin, C. Fisher, J. Greengard, 1994, Protein science : a publication of the Protein Society.

Activation of protein C during reperfusion in clinical liver transplantation

José A Fernández, J. Griffin, H. Repo, 2003, Transplantation.

Activation of Purified C1, The First Complement Component, by Purified Plasma Kallikrein and Plasmin

J. Griffin, N. Cooper, L. Miles, 1979 .

Protein C inhibitor is expressed in tubular cells of human kidney.

J. Griffin, J. A. Fernandez, D. Loskutoff, 1994, The Journal of clinical investigation.

Intrinsic stability and functional properties of disulfide bond‐stabilized coagulation factor VIIIa variants

J. Griffin, J. Pellequer, K. Radtke, 2006, Journal of thrombosis and haemostasis : JTH.

Skeletal muscle myosin promotes coagulation by binding factor XI via its A3 domain and enhancing thrombin-induced factor XI activation

O. McCarty, J. Griffin, A. Gruber, 2022, The Journal of biological chemistry.

Synergistic Effect in Bleed Reduction By superfva and Recombinant Human FVIIa in Vivo Suggests a Novel Bypassing Strategy for Hemophilia Patients with Inhibitors

J. Griffin, V. Bhat, A. Drygalski, 2014 .

Circulating inhibitors of blood coagulation associated with procainamide‐induced lupus erythematosus

J. Griffin, B. Furie, B. Furie, 1978, American journal of hematology.

Safety, Stability and Pharmacokinetic Properties of superFactor Va, a Novel Engineered Coagulation Factor V for Treatment of Severe Bleeding

J. Griffin, J. Pellequer, V. Bhat, 2016, Pharmaceutical Research.

An Engineered Factor Fva Prevents Bleeding Induced By Anticoagulant Wild Type Activated Protein C

J. Griffin, A. Drygalski, A. Gale, 2013 .

Rhodium(II) acetate catalyzed hydrocarbon oxidations by molecular oxygen

J. Griffin, C. Winter, M. Doyle, 1984 .

Metalloregulation in the Sequence Specific Binding of Synthetic Molecules to DNA

J. Griffin, P. Dervan, 1987 .

Procatalysts for carbenoid transformations

J. Griffin, M. Doyle, Jose Da Conceicão, 1985 .

Stereoselectivity of catalytic cyclopropanation reactions. Catalyst dependence in reactions of ethyl diazoacetate with alkenes

J. Griffin, M. Doyle, M. Trudell, 1984 .

Correlations between catalytic reactions of diazo compounds and stoichiometric reactions of transition-metal carbenes with alkenes. Mechanism of the cyclopropanation reaction

J. Griffin, V. Bagheri, M. Doyle, 1984 .

Steric and Electronic Effects, Enantiospecificity, and Reactive Orientation in DNA Binding/Cleaving by Substituted Derivatives of [SalenMn(III)](+).

J. Griffin, D. Gravert, 1996, Inorganic chemistry.

NUCLEAR MAGNETIC RESONANCE STUDIES OF A RIBONUCLEASE‐DINUCLEOSIDE PHOSPHONATE COMPLEX AND THEIR IMPLICATIONS FOR THE MECHANISM OF THE ENZYME

A. Schechter, J. Griffin, J. S. Cohen, 1973, Annals of the New York Academy of Sciences.

Stereoselectivity of catalytic cyclopropanation reactions. Catalyst dependence in reactions of ethyl diazoacetate with alkenes

J. Griffin, M. Doyle, M. Trudell, 1984 .

Correlations between catalytic reactions of diazo compounds and stoichiometric reactions of transition-metal carbenes with alkenes. Mechanism of the cyclopropanation reaction

J. Griffin, V. Bagheri, M. Doyle, 1984 .

Protein synthesis by native chemical ligation: expanded scope by using straightforward methodology.

J. Griffin, P. Dawson, T. Hackeng, 1999, Proceedings of the National Academy of Sciences of the United States of America.

Carbon-13 nuclear magnetic resonance studies of the binding of selectively 13C-enriched oxytocins to the neurophypophyseal protein, bovine neurophysin II.

J. Griffin, P. Nicolas, P. Cohen, 1977, Biochemistry.

Selectively enriched carbon-13-labeled proline-7 and carbon-13-labeled leucine-8 ocytocins as probes for the analysis of peptide hormone interactions with bovine neurophysin I using carbon-13 nuclear magnetic resonance spectroscopy

J. Griffin, P. Nicolas, P. Cohen, 1977 .

Activated protein C resistance: molecular mechanisms based on studies using purified Gln506-factor V.

J. Griffin, M. J. Heeb, Y. Kojima, 1995, Blood.

Drug-biomolecule interactions: proton magnetic resonance studies of complex formation between bovine neurophysins and oxytocin at molecular level.

J. Griffin, M. Camier, P. Cohen, 1975, Journal of pharmaceutical sciences.

Persistent penile erection in infancy.

J. Griffin, C. Firlit, G. Seremetis, 1997, The Journal of urology.

Carbamyl phosphate binding to aspartate transcarbamylase. Partial saturation and its alteration by succinate.

J. Rosenbusch, J. Griffin, 1973, The Journal of biological chemistry.

Inhibition of 2,3-oxidosqualene-lanosterol cyclase in Candida albicans by pyridinium ion-based inhibitors

J. Griffin, J. Capobianco, D. Zakula, 1996, Antimicrobial agents and chemotherapy.

Potent Anti-Trypanosoma cruzi Activities of Oxidosqualene Cyclase Inhibitors

F. Buckner, J. Griffin, W. V. Van Voorhis, 2001, Antimicrobial Agents and Chemotherapy.

Sequence-Specific Chiral Recognition of Right-Handed Double-Helical DNA by (2S,3S)- (Ia) and (2R,3R)-Dihydroxybis(netropsin)succinamide (Ib).

J. Griffin, P. Dervan, 1986 .

High molecular weight kininogen receptor.

J. Griffin, J. Greengard, 1992, Methods in enzymology.

Interactions and inhibition of blood coagulation factor Va involving residues 311–325 of activated protein C

J. Griffin, R. Mesters, M. J. Heeb, 1993, Protein science : a publication of the Protein Society.

The Hageman Factor System: Mechanism of Contact Activation

J. Griffin, C. Cochrane, S. Revak, 1976 .

Reagents and methods for the solid-phase synthesis of protein-EDTA for use in affinity cleaving

D. P. Mack, J. Griffin, P. Dervan, 1990 .

Nuclear magnetic resonance titration curves of histidine ring protons. IV. The effects of phosphate and sulfate on ribonuclease.

A. Schechter, J. Griffin, J. Cohen, 1973, The Journal of biological chemistry.

Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective

José A Fernández, Dong Liu, J. Griffin, 2003, Nature Medicine.

Activated protein C inhibits neutrophil extracellular trap formation in vitro and activation in vivo

Laura D. Healy, José A Fernández, O. McCarty, 2017, The Journal of Biological Chemistry.

Blood coagulation factor Va abnormality associated with resistance to activated protein C in venous thrombophilia.

J. Griffin, B. Evatt, X. Sun, 1994, Blood.

Isolation and characterization of the gene encoding 2,3-oxidosqualene-lanosterol cyclase from Saccharomyces cerevisiae.

J. Griffin, Z. Shi, C. Buntel, 1994, Proceedings of the National Academy of Sciences of the United States of America.

Neurotoxicity of the anticoagulant-selective E149A-activated protein C variant after focal ischemic stroke in mice.

J. Griffin, B. Zlokovic, Yaoming Wang, 2013, Blood cells, molecules & diseases.

Activated protein C therapy slows ALS-like disease in mice by transcriptionally inhibiting SOD1 in motor neurons and microglia cells.

Lee D. Hallagan, José A Fernández, R. Deane, 2009, The Journal of clinical investigation.

The cytoprotective protein C pathway.

J. Griffin, B. Zlokovic, L. Mosnier, 2007, Blood.

A novel exosite in the light chain of human activated protein C essential for interaction with blood coagulation factor Va.

J. Griffin, R. Mesters, M. J. Heeb, 1993, Biochemistry.

Novel exomic rare variants associated with venous thrombosis

A. Torkamani, J. Griffin, H. Deguchi, 2020, British journal of haematology.

Stroke Treatment With PAR-1 Agents to Decrease Hemorrhagic Transformation

J. Griffin, B. Zlokovic, P. Lyden, 2021, Frontiers in Neurology.

Involvement of amino acid residues 423-429 of human protein S in binding to C4b-binding protein.

P. Reitsma, J. Griffin, J. A. Fernandez, 1998, Blood cells, molecules & diseases.

Two Mutations in the Promoter Region of the Human Protein C Gene Both Cause Type I Protein C Deficiency by Disruption of Two HNF-3 Binding Sites (*)

P. Reitsma, J. Griffin, R. Bertina, 1995, The Journal of Biological Chemistry.

3K3A-activated protein C blocks amyloidogenic BACE1 pathway and improves functional outcome in mice

J. Griffin, B. Zlokovic, A. Nikolakopoulou, 2019, The Journal of experimental medicine.

The Western Australian Aboriginal Child Health Survey: Forced Separation from Natural Family, Forced Relocation from Traditional Country or Homeland, and Social and Emotional Wellbeing of Aboriginal Children and Young People: Additional notes

S. Zubrick, S. Silburn, J. Griffin, 2005 .

Potent blood coagulant activity of human semen due to prostasome-bound tissue factor.

José A Fernández, J. Griffin, K. Radtke, 1997, Biology of reproduction.

Extensive venous and arterial thrombosis associated with an inhibitor to activated protein C.

José A Fernández, H. Halkin, J. Griffin, 1999, Blood.

The Frequency of Type I Heterozygous Protein S and Protein C Deficiency in 141 Unrelated Young Patients with Venous Thrombosis

J. Griffin, I. Scharrer, C. Gladson, 1988, Thrombosis and Haemostasis.

Effect of hyperhomocysteinemia on protein C activation and activity.

José A Fernández, J. Griffin, T. Bottiglieri, 2002, Blood.

Protein C anticoagulant and cytoprotective pathways

J. Griffin, B. Zlokovic, L. Mosnier, 2012, International Journal of Hematology.

Protein C anticoagulant activity in relation to anti-inflammatory and anti-apoptotic activities.

J. Griffin, L. Mosnier, 2006, Frontiers in bioscience : a journal and virtual library.

Interaction of Plasma Kallikrein with Protein C Inhibitor in Purified Mixtures and in Plasma

J. Griffin, F. España, A. Estellés, 1991, Thrombosis and Haemostasis.

Interaction of human plasma kallikrein and its light chain with C1 inhibitor.

J. Griffin, B. Bouma, F. van der Graaf, 1983, Biochemistry.

Surface and fluid phase activities of two forms of activated Hageman factor produced during contact activation of plasma

J. Griffin, C. Cochrane, B N Bouma, 1978, The Journal of experimental medicine.

Properties of sulfatides in factor-XII-dependent contact activation.

J. Griffin, G. Tans, 1982, Blood.

Detection and Quantitation of Cleaved and Uncleaved High Molecular Weight Kininogen in Plasma by Ligand Blotting with Radiolabeled Plasma Prekallikrein or Factor XI

B. Lämmle, J. Griffin, J. Curd, 1988, Thrombosis and Haemostasis.

Evidence for the Regulation of Urokinase and Tissue Type Plasminogen Activators by the Serpin, Protein C Inhibitor, in Semen and Blood Plasma

J. Griffin, J. Gilabert, F. España, 1993, Thrombosis and Haemostasis.

Receptors for high molecular weight kininogen on stimulated washed human platelets.

J. Griffin, J. Greengard, 1984, Biochemistry.

Acylcarnitines are anticoagulants that inhibit factor Xa and are reduced in venous thrombosis, based on metabolomics data.

José A Fernández, G. Siuzdak, J. Griffin, 2015, Blood.

Arteriovenous Blood Metabolomics: A Readout of Intra-Tissue Metabostasis

Caroline H. Johnson, G. Siuzdak, Mohit M. Jain, 2015, Scientific Reports.

Inhibition of thrombus formation by activated recombinant protein C in a primate model of arterial thrombosis.

J. Griffin, A. Gruber, S. Hanson, 1990, Circulation.

Species-specific anticoagulant and mitogenic activities of murine protein S

José A Fernández, J. Griffin, B. Zlokovic, 2009, Haematologica.

Identification of residues 413-433 of plasma protein S as essential for binding to C4b-binding protein.

J. Griffin, J. Fernandez, M. Heeb, 1993, The Journal of biological chemistry.

Chemical synthesis of human protein S thrombin-sensitive module and first epidermal growth factor module.

S. Kent, J. Griffin, P. Dawson, 1998, Biopolymers.

C-terminal Residues 621–635 of Protein S Are Essential for Binding to Factor Va*

J. Griffin, J. Rosing, G. Tans, 1999, The Journal of Biological Chemistry.

Quantitative Immunoblotting of Plasma and Platelet Protein S

B. Lämmle, J. Griffin, H. Schwarz, 1986, Thrombosis and Haemostasis.

Quantitative immunoblotting assay of blood coagulation factor XII.

B. Lämmle, J. Griffin, H. Schwarz, 1986, Thrombosis research.

Functional Assays for Protein C Activity and Protein C Inhibitor Activity in Plasma

J. Griffin, M. Geiger, Teresa White, 1989, Thrombosis and Haemostasis.

Decreased Plasma Levels of Protein S in Well-Controlled Type I Diabetes Mellitus

J. Griffin, G. Schernthaner, H. Schwarz, 1987, Thrombosis and Haemostasis.

Effect of L-asparaginase therapy for acute lymphoblastic leukemia on plasma vitamin K-dependent coagulation factors and inhibitors.

G. Leverger, J. Griffin, L. Drouet, 1986, The Journal of pediatrics.

Prognostic value of protein C concentrations in neutropenic patients at high risk of severe septic complications

José A Fernández, J. Helterbrand, J. Griffin, 2000, Critical care medicine.

Inhibition of activated protein C by recombinant alpha 1-antitrypsin variants with substitution of arginine or leucine for methionine358.

R. Bischoff, J. Griffin, M. Courtney, 1990, The Journal of biological chemistry.

Low protein Z levels and risk of ischemic stroke: differences by diabetic status and gender.

A. Paganini-Hill, J. Griffin, M. Fisher, 2002, Blood cells, molecules & diseases.

Purification and characterization of two functionally distinct forms of C1 inhibitor from a patient with angioedema.

J. Griffin, D. A. Mathison, J. Curd, 1981, Clinical and experimental immunology.

The function of the heavy and light chain of human plasma kallikrein in the activation of factor XII.

J. Griffin, J. Rosing, G. Tans, 1986, Advances in experimental medicine and biology.

Surface-dependent activation of human factor XII (Hageman factor) by kallikrein and its light chain.

J. Griffin, J. Rosing, G. Tans, 1985, European journal of biochemistry.

Rabbit blood coagulation factor XI. Mechanism of activation of rabbit Hageman factor (factor XII).

J. Griffin, C. Cochrane, R. Wiggins, 1979, Thrombosis research.

Role of surface in surface-dependent activation of Hageman factor (blood coagulation factor XII).

J. Griffin, 1978, Proceedings of the National Academy of Sciences of the United States of America.

Immunoblotting studies of coagulation factor XII, plasma prekallikrein, and high molecular weight kininogen.

B. Lämmle, J. Griffin, M. Berrettini, 1987, Seminars in thrombosis and hemostasis.

Overview on Blood Coagulation Proteins

J. Griffin, J. E. Gardiner, 1984 .

Homology models of the C domains of blood coagulation factors V and VIII: a proposed membrane binding mode for FV and FVIII C2 domains.

E. Getzoff, J. Griffin, J. Pellequer, 1998, Blood cells, molecules & diseases.

Sulfatide bilayers as a surface for contact activation in human plasma.

J. Griffin, A. Verkleij, J. Yu, 1987, Biochemical and biophysical research communications.

Activated protein C: biased for translation.

J. Griffin, B. Zlokovic, L. Mosnier, 2015, Blood.

Combined neurothrombectomy or thrombolysis with adjunctive delivery of 3K3A-activated protein C in acute ischemic stroke

J. Griffin, B. Zlokovic, A. Amar, 2015, Front. Cell. Neurosci..

Design of a DNA-Programmed Plasminogen Activator.

M. Ghadiri, J. Griffin, L. Leman, 2018, Journal of the American Chemical Society.

Characterization of a Factor Xa Binding Site on Factor Va near the Arg-506 Activated Protein C Cleavage Site*

J. Griffin, J. Pellequer, X. Xu, 2007, Journal of Biological Chemistry.

Cytoprotective-selective activated protein C therapy for ischaemic stroke

J. Griffin, B. Zlokovic, L. Mosnier, 2014, Thrombosis and Haemostasis.

Organ-Specific Protection Against Lipopolysaccharide-Induced Vascular Leak Is Dependent on the Endothelial Protein C Receptor

J. Griffin, W. Ruf, C. Furlan-Freguia, 2013, Arteriosclerosis, thrombosis, and vascular biology.

Biased agonism of protease-activated receptor 1 by activated protein C caused by noncanonical cleavage at Arg46.

J. Griffin, R. Sinha, E. Bouwens, 2012, Blood.

Cytoprotective protein C pathways and implications for stroke and neurological disorders

J. Griffin, B. Zlokovic, 2011, Trends in Neurosciences.

Endotoxemia and sepsis mortality reduction by non-anticoagulant–activated protein C

Nigel Mackman, Edward J. Kerschen, John H. Griffin, 2007, The Journal of experimental medicine.

Key Points * R 41 Q and R 46 Q point mutations in PAR 1 in mice enabled studies of APC ’ s in vivo mechanism of action in lethal sepsis and ischemic stroke

José A Fernández, J. Griffin, B. Zlokovic, 2018 .

Activated protein C targets CD8+ dendritic cells to reduce the mortality of endotoxemia in mice.

José A Fernández, J. Griffin, M. Hessner, 2010, The Journal of clinical investigation.

Elucidating the structural chemistry of glycosaminoglycan recognition by protein C inhibitor.

J. Tainer, L. Kuhn, J. Griffin, 1990, Proceedings of the National Academy of Sciences of the United States of America.

Cytoprotective-selective activated protein C attenuates Pseudomonas aeruginosa-induced lung injury in mice.

José A Fernández, M. Cohen, J. Griffin, 2011, American journal of respiratory cell and molecular biology.

Activated Protein C Mutant with Minimal Anticoagulant Activity, Normal Cytoprotective Activity, and Preservation of Thrombin Activable Fibrinolysis Inhibitor-dependent Cytoprotective Functions*

J. Griffin, Xia V. Yang, L. Mosnier, 2007, Journal of Biological Chemistry.

Activated Protein C Prevents Neuronal Apoptosis via Protease Activated Receptors 1 and 3

José A Fernández, J. Griffin, B. Zlokovic, 2004, Neuron.

Protein S Protects Neurons from Excitotoxic Injury by Activating the TAM Receptor Tyro3–Phosphatidylinositol 3-Kinase–Akt Pathway through Its Sex Hormone-Binding Globulin-Like Region

José A Fernández, J. Griffin, B. Zlokovic, 2010, The Journal of Neuroscience.

Urinary protein C inhibitor. Glycosaminoclycans synthesized by the epithelial kidney cell line TCL-598 enhance its interaction with urokinase.

J. Griffin, B. Binder, M. Geiger, 1991, The Journal of biological chemistry.

A single genetic origin for a common Caucasian risk factor for venous thrombosis.

J. Griffin, I. Pabinger, A. Eldor, 1997, Blood.

3K3A-Activated Protein C Prevents Microglia Activation, Inhibits NLRP3 Inflammasome and Limits Ocular Inflammation

José A Fernández, D. Weinberger, J. Griffin, 2022, International journal of molecular sciences.

Inhibition of staurosporine-induced apoptosis of endothelial cells by activated protein C requires protease-activated receptor-1 and endothelial cell protein C receptor.

J. Griffin, L. Mosnier, 2003, The Biochemical journal.

Upregulation of the antithrombotic protein C pathway at birth.

V. Fellman, J. Griffin, J. Petäjä, 1998, Pediatric hematology and oncology.

Apolipoprotein E Receptor 2 Mediates Activated Protein C–Induced Endothelial Akt Activation and Endothelial Barrier Stabilization

José A Fernández, J. Griffin, Xia V. Yang, 2016, Arteriosclerosis, thrombosis, and vascular biology.

Possible Structural Implications of 20 Mutations in the Protein C Protease Domain

J. Griffin, C. Fisher, J. Greengard, 1994, Thrombosis and Haemostasis.

Identification of candidate residues for interaction of protein S with C4b binding protein and activated protein C.

J. Griffin, K. Radtke, J. Greengard, 1995, The Biochemical journal.

Quantitative immunoassay for complexes of prostate-specific antigen with alpha2-macroglobulin.

J. Griffin, J. Gilabert, F. España, 1996, Clinical chemistry.

Prostate specific antigen-alpha 2-macroglobulin complexes in prostate cancer patient sera.

R. Gittes, J. Griffin, F. España, 1995, Biochemistry and molecular biology international.

Plasma Lipoproteins, Hemostasis and Thrombosis

José A Fernández, J. Griffin, J H Griffin, 2001, Thrombosis and Haemostasis.

High-density lipoprotein enhancement of anticoagulant activities of plasma protein S and activated protein C.

José A Fernández, J. Griffin, L. Curtiss, 1999, The Journal of clinical investigation.

Cytoprotective signaling by activated protein C requires protease-activated receptor-3 in podocytes.

C. Esmon, J. Griffin, T. Madhusudhan, 2012, Blood.

Impairments of the protein C system and fibrinolysis in infection-associated stroke.

José A Fernández, Michael Fisher, R. Macko, 1996, Stroke.

Activated Protein C Promotes Neovascularization and Neurogenesis in Postischemic Brain via Protease-Activated Receptor 1

José A Fernández, J. Griffin, B. Zlokovic, 2008, The Journal of Neuroscience.

Activated protein C and ischemic stroke

José A Fernández, J. Griffin, B. Zlokovic, 2004, Critical care medicine.

High-Density Lipoprotein Deficiency and Dyslipoproteinemia Associated With Venous Thrombosis in Men

J. Griffin, H. Deguchi, D. Elias, 2005, Circulation.

Safety and cost-effectiveness of early discharge after primary angioplasty in low risk patients with acute myocardial infarction. PAMI-II Investigators. Primary Angioplasty in Myocardial Infarction.

G. Stone, L. Grines, W. O’Neill, 1998, Journal of the American College of Cardiology.

Elevated CETP Lipid Transfer Activity is Associated with the Risk of Venous Thromboembolism

J. Griffin, Yajnavalka Banerjee, H. Deguchi, 2016, Journal of atherosclerosis and thrombosis.

Interactions of bovine neurophysins with neurohypophyseal hormones. On the role of tyrosine-49.

J. Griffin, M. Camier, P. Cohen, 1975, The Journal of biological chemistry.

Complex formation between bovine neurophysin-I and oxytocin, vasopressin, and tripeptide analogs of their NH2-terminal region. Absorbance and circular dichroism difference spectroscopic studies.

J. Griffin, P. Cohen, R. Alazard, 1973, The Journal of biological chemistry.

Structural basis for type I and type II deficiencies of antithrombotic plasma protein C: Patterns revealed by three‐dimensional molecular modelling of mutations of the protease domain

J. Griffin, B. Villoutreix, C. Fisher, 1994, Proteins.

Interdomain engineered disulfide bond permitting elucidation of mechanisms of inactivation of coagulation factor Va by activated protein C

Jean-Luc Pellequer, E. Getzoff, J. Griffin, 2002, Protein science : a publication of the Protein Society.

A novel ELISA for mouse activated protein C in plasma.

José A Fernández, D. Dwyre, J. Griffin, 2006, Journal of immunological methods.

Protein C pathway impairment in nonsymptomatic cigarette smokers.

José A Fernández, J. Griffin, A. Gruber, 2002, Blood cells, molecules & diseases.

A prospective, multicenter, international randomized trial comparing four reperfusion strategies in acute myocardial infarction: Principal report of the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial

J. Carroll, G. Stone, C. Grines, 2001 .

The Western Australian Aboriginal Child Health Survey: Measuring the social and emotional wellbeing of Aboriginal children and the intergenerational effects of forced separation

S. Zubrick, S. Silburn, J. Griffin, 2005 .

Nucleotide and deduced amino acid sequences of the oxidosqualene cyclase from Candida albicans

J. Griffin, C. Buntel, 1992 .

Conversion of a plant oxidosqualene-cycloartenol synthase to an oxidosqualene-lanosterol cyclase by random mutagenesis.

J. Griffin, Tung-Kung Wu, 2002, Biochemistry.

The scrotal hitch for hemostasis and edema prevention in scrotal surgery.

J. Griffin, J. Canning, 1996, Urology.

Plasma concentrations of the natural anticoagulants protein C and protein S in patients with proteinuria.

F. Cosio, J. Griffin, J. Brandt, 1985, The Journal of laboratory and clinical medicine.

Plasma protein S contains zinc essential for efficient activated protein C‐independent anticoagulant activity and binding to factor Xa, but not for efficient binding to tissue factor pathway inhibitor

J. Griffin, B. Bouma, M. Heeb, 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

Chemical synthesis and spontaneous folding of a multidomain protein: anticoagulant microprotein S.

S. Kent, J. Griffin, P. Dawson, 2000, Proceedings of the National Academy of Sciences of the United States of America.

Conformational changes in activated protein C caused by binding of the first epidermal growth factor-like module of protein S.

J. Griffin, T. Hackeng, A. Johnson, 2000, The Biochemical journal.

Activated protein C ligation of ApoER2 (LRP8) causes Dab1-dependent signaling in U937 cells

Hiroshi Deguchi, John H. Griffin, José A Fernández, 2009, Proceedings of the National Academy of Sciences.

Design, synthesis and in vitro evaluation of pyridinium ion based cyclase inhibitors and antifungal agents.

J. Griffin, J. Capobianco, D. Zakula, 1996, Bioorganic & medicinal chemistry.

Coronary Plaque Morphology and Frequency of Ulceration Distant From Culprit Lesions in Patients With Unstable and Stable Presentation

G. Stone, C. Grines, E. Tuzcu, 2003, Arteriosclerosis, thrombosis, and vascular biology.

Activated protein C

José A Fernández, J. Griffin, A. Gale, 2007, Journal of thrombosis and haemostasis : JTH.

C‐terminal residues of activated protein C light chain contribute to its anticoagulant and cytoprotective activities

M. Sanner, J. Griffin, Yuqi Zhang, 2020, Journal of thrombosis and haemostasis : JTH.

Characterization of a thrombomodulin binding site on protein C and its comparison to an activated protein C binding site for factor Va

J. Griffin, A. Gale, 2004, Proteins.

Prothrombin amino terminal region helps protect coagulation factor Va from proteolytic inactivation by activated protein C

J. Griffin, A. Gale, S. Yegneswaran, 2008, Thrombosis and Haemostasis.

Prothrombotic skeletal muscle myosin directly enhances prothrombin activation by binding factors Xa and Va.

O. McCarty, M. Cohen, J. Griffin, 2016, Blood.

The assignment of an exchangeable low-field NH proton resonance of ribonuclease A to the active-site histidine-119.

A. Schechter, J. Griffin, J. Cohen, 1973, Biochemistry.

Elevated serum amyloid A is associated with venous thromboembolism

J. Griffin, F. España, H. Deguchi, 2012, Thrombosis and Haemostasis.

Platelet protein S limits venous but not arterial thrombosis propensity by controlling coagulation in the thrombus.

José A Fernández, J. Griffin, Y. Matsumura, 2020, Blood.

Hormonal interactions at the molecular level: A high resolution proton magnetic resonance study of bovine neurophysins and their interactions with oxytocin

J. Griffin, J. S. Cohen, P. Fromageot, 1972, FEBS letters.

Cardiac and Skeletal Muscle Myosin Exert Procoagulant Effects.

A. Sauaia, E. Moore, M. Cohen, 2019, Shock.

Rapid Communication: Cardiac and Skeletal Muscle Myosin Exert Procoagulant Effects.

A. Sauaia, E. Moore, M. Cohen, 2019, Shock.

Structural Basis for Hemophilia A Caused by Mutations in the C Domains of Blood Coagulation Factor VIII

E. Getzoff, J. Griffin, J. Pellequer, 2000, Thrombosis and Haemostasis.

Blood coagulation factor Va abnormality associated with resistance to activated protein C in venous thrombophilia

J. Griffin, B. Evatt, Xi Sun, 1994 .

High-Density Lipoprotein and the Risk of Recurrent Venous Thromboembolism

M. Schemper, J. Griffin, S. Eichinger, 2007, Circulation.

Addendum: American College of Medical Genetics consensus statement on factor V Leiden mutation testing

W. Grody, J. Griffin, Annette K. Taylor, 2021, Genetics in Medicine.

The active site of staphylococcal nuclease: paramagnetic relaxation of bound nucleotide inhibitor nuclei by lanthanide ions.

A. Schechter, J. Griffin, B. Furie, 1974, Proceedings of the National Academy of Sciences of the United States of America.

Pharmacological targeting of the thrombomodulin–protein C pathway mitigates radiation toxicity

José A Fernández, A. Schambach, L. Fink, 2012, Nature Medicine.

Pharmacological targeting of the thrombomodulin – activated protein C pathway mitigates radiation toxicity

José A Fernández, A. Schambach, L. Fink, 2022 .

Can adjunctive therapies augment the efficacy of endovascular thrombolysis? A potential role for activated protein C

J. Griffin, B. Zlokovic, Yaoming Wang, 2017, Neuropharmacology.

Non-Canonical Cleavage of Protease Activated Receptor 1 (PAR1) by Activated Protein C Provides Novel Insights Into the Repertoire of Cytoprotective and Proinflammatory PAR1 Signaling

J. Griffin, L. Mosnier, 2011 .

Activated protein C and PAR1‐derived and PAR3‐derived peptides are anti‐inflammatory by suppressing macrophage NLRP3 inflammasomes

Laura D. Healy, José A Fernández, J. Griffin, 2020, Journal of thrombosis and haemostasis : JTH.

Inhibition and complexation of activated protein C by two major inhibitors in plasma.

J. Griffin, F. España, M. Heeb, 1989, Blood.

CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Extensive Venous and Arterial Thrombosis Associated With an Inhibitor to Activated Protein C

H. Halkin, J. Griffin, U. Martinowitz, 2016 .

Analysis of the urinary metabolic profiles in irradiated rats treated with Activated Protein C (APC), a potential mitigator of radiation toxicity

José A Fernández, M. Boerma, J. Griffin, 2023, International journal of radiation biology.

Three-dimensional Model of Coagulation Factor Va Bound to Activated Protein C

E. Getzoff, J. Griffin, J. Pellequer, 2000, Thrombosis and Haemostasis.

The autolysis loop of activated protein C interacts with factor Va and differentiates between the Arg506 and Arg306 cleavage sites.

J. Griffin, A. Gale, M. Heeb, 2000, Blood.

Safety, Stability and Pharmacokinetic Properties of superFactor Va, a Novel Engineered Coagulation Factor V for Treatment of Severe Bleeding

J. Griffin, J. Pellequer, V. Bhat, 2016, Pharmaceutical Research.

REARRANGEMENTS OF YLIDES GENERATED FROM REACTIONS OF DIAZO COMPOUNDS WITH ALLYL ACETALS AND THIOKETALS BY CATALYTIC METHODS. HETEROATOM ACCELERATION OF THE (2,3)-SIGMATROPIC REARRANGEMENT

J. Griffin, M. Doyle, M. S. Chinn, 1984 .

Protection of ischemic white matter and oligodendrocytes in mice by 3K3A-activated protein C

Mikko T. Huuskonen, José A Fernández, J. Griffin, 2021, The Journal of experimental medicine.

Activated protein C analog promotes neurogenesis and improves neurological outcome after focal ischemic stroke in mice via protease activated receptor 1

J. Griffin, B. Zlokovic, Yaoming Wang, 2013, Brain Research.

Protein C supports platelet binding and activation under flow: role of glycoprotein Ib and apolipoprotein E receptor 2

José A Fernández, O. McCarty, J. Griffin, 2008, Journal of thrombosis and haemostasis : JTH.

Application of nuclear magnetic resonance spectroscopy to proteins.

A. Schechter, J. Griffin, B. Furie, 1975, Biochimie.

Urinary Metabolomics for the Prediction of Radiation-Induced Cardiac Dysfunction

José A Fernández, M. Boerma, J. Griffin, 2023, Metabolites.

Factor V as Anticoagulant Cofactor for Activated Protein C in Factor Va Inactivation

J. Griffin, A. Gale, T. Cramer, 2008 .

Activated protein C light chain provides an extended binding surface for its anticoagulant cofactor, protein S.

José A Fernández, M. Sanner, J. Griffin, 2017, Blood advances.

Low levels of activated protein C in patients with systemic lupus erythematosus do not relate to lupus anticoagulants but to low levels of factor II

J. Griffin, P. D. de Groot, M. Simmelink, 2002, British journal of haematology.

Conformational changes in aspartate trancarbamylase. I. Studies of ligand binding and of subunit interactions by circular dichroism spectroscopy.

E. Blout, J. Rosenbusch, J. Griffin, 1972, The Journal of biological chemistry.

Sex-dependent effects of genetic upregulation of activated protein C on delayed effects of acute radiation exposure in the mouse heart, small intestine, and skin

José A Fernández, M. Boerma, Preeti Singh, 2021, PloS one.

Mechanisms for Mortality Reduction by Activated Protein C in Severe Sepsis.

José A Fernández, J. Griffin, S. Coughlin, 2006 .

Molecular Characterization of an Extended Binding Site for Coagulation Factor Va in the Positive Exosite of Activated Protein C*

J. Griffin, A. Gale, A. Tsavaler, 2002, The Journal of Biological Chemistry.

Analysis of protein S C4b-binding protein interactions by homology modeling and inhibitory antibodies.

J. Griffin, B. Villoutreix, T. Hackeng, 1994, Biochemistry.

Protein S, an Antithrombotic Factor, Is Synthesized and Released by Neural Tumor Cells

José A Fernández, J. Griffin, B. Evatt, 1993, Journal of neurochemistry.

3K3A-Activated Protein C Inhibits Choroidal Neovascularization Growth and Leakage and Reduces NLRP3 Inflammasome, IL-1β, and Inflammatory Cell Accumulation in the Retina

José A Fernández, D. Weinberger, J. Griffin, 2023, International journal of molecular sciences.

Immunological Studies Of Human Factor XI

J. Griffin, B. Bouma, R. Vlooswijk, 1981, Thrombosis and Haemostasis.

bloodjournal.hematologylibrary.org at PENN STATE UNIVERSITY on February 21, 2013. For personal use only. The cytoprotective protein C pathway

J. Griffin, B. Zlokovic, L. Mosnier, 2006 .

The cytoprotective protein C pathway.

J. Griffin, B. Zlokovic, L. Mosnier, 2007 .

Activated protein C.

José A Fernández, J. Griffin, A. Gale, 2007 .

Protective Effect of Activated Protein C in Murine Endotoxemia: Mechanism of Action.

J. Griffin, F. Castellino, E. Kerschen, 2005 .

Activated protein C correlates inversely with thrombin levels in resting healthy individuals

José A Fernández, J. Griffin, A. Gruber, 1997, American journal of hematology.

The cytoprotective protein C pathway

J. Griffin, B. Zlokovic, L. Mosnier, 2007 .

Comparative modeling of the three CP modules of the beta-chain of C4BP and evaluation of potential sites of interaction with protein S.

J. Griffin, B. Villoutreix, O. Teleman, 1995, Protein engineering.

A protein S binding site on C4b-binding protein involves beta chain residues 31-45.

J. Griffin, J. Fernandez, 1994, The Journal of biological chemistry.

Characterization of a cDNA for Rhesus Monkey Protein C Inhibitor – Evidence for N-Terminal Involvement in Heparin Stimulation

José A Fernández, J. Griffin, B. Villoutreix, 1995, Thrombosis and Haemostasis.

Thrombin-mediated activation of PAR1 enhances doxorubicin-induced cardiac injury in mice

J. Griffin, N. Mackman, S. Grover, 2022, Blood advances.

Prostate carcinoma metastatic to the penis: magnetic resonance imaging and brachytherapy.

J. Griffin, E. Melian, J. Wheeler, 1996, Journal of Urology.

Endothelial and Antithrombotic Actions of HDL

J. Griffin, C. Mineo, P. Shaul, 2006 .

L-Cysteine-, L-Methionine- and D-Penicillamine-Derived Ligands for Transition Metal Catalyzed Carbon-Carbon Bond Forming Reactions.

J. Griffin, R. Kellogg, 1986 .

Superior in Vivo Hemostatic Properties of an Engineered Factor Va Variant for Hemophilia Mice

J. Griffin, A. Drygalski, A. Gale, 2012 .

Human protein C and thromboembolic disease.

J. Griffin, J. E. Gardiner, 1983, Progress in hematology.

Plasma protein S deficiency and thromboembolic disease.

J. Griffin, H. Schwarz, M. Heeb, 1987, Progress in hematology.

Anti-Inflammatory and Anti-Apoptotic Activities of Activated Protein C Are Independent of Anticoagulant Activity.

J. Griffin, Xia V. Yang, L. Mosnier, 2006 .

Activated protein C targets CD8+ dendritic cells to reduce the mortality of endotoxemia in mice.

José A Fernández, J. Griffin, M. Hessner, 2010, The Journal of clinical investigation.

Activated protein C therapy slows ALS-like disease in mice by transcriptionally inhibiting SOD1 in motor neurons and microglia cells.

Lee D. Hallagan, José A Fernández, R. Deane, 2009, The Journal of clinical investigation.

3K3A–activated protein C stimulates postischemic neuronal repair by human neural stem cells in mice

S. Goldman, J. Griffin, B. Zlokovic, 2016, Nature Medicine.

Cytoprotective-selective activated protein C attenuates Pseudomonas aeruginosa-induced lung injury in mice.

José A Fernández, M. Cohen, J. Griffin, 2011, American journal of respiratory cell and molecular biology.

3K3A-activated protein C blocks amyloidogenic BACE1 pathway and improves functional outcome in mice

J. Griffin, B. Zlokovic, A. Nikolakopoulou, 2019, The Journal of experimental medicine.

An Activated Protein C Analog With Reduced Anticoagulant Activity Extends the Therapeutic Window of Tissue Plasminogen Activator for Ischemic Stroke in Rodents

M. Chopp, J. Griffin, Zhenggang Zhang, 2012, Stroke.

Cardiolipin is a normal component of human plasma lipoproteins.

José A Fernández, J. Griffin, T. Hackeng, 2000, Proceedings of the National Academy of Sciences of the United States of America.

Activated protein C resistance: molecular mechanisms based on studies using purified Gln506-factor V.

J. Griffin, Y. Kojima, J. Greengard, 1995, Blood.

Acylcarnitines are anticoagulants that inhibit factor Xa and are reduced in venous thrombosis, based on metabolomics data.

José A Fernández, G. Siuzdak, J. Griffin, 2015, Blood.

Cytoprotective-selective activated protein C therapy for ischaemic stroke

J. Griffin, B. Zlokovic, L. Mosnier, 2014, Thrombosis and Haemostasis.

Factor V Is an Anticoagulant Cofactor for Activated Protein C during Inactivation of Factor Va

J. Griffin, A. Gale, Thomas J. Cramer, 2010, Pathophysiology of Haemostasis and Thrombosis.

Activated protein C: biased for translation.

J. Griffin, B. Zlokovic, L. Mosnier, 2015, Blood.

Organ-Specific Protection Against Lipopolysaccharide-Induced Vascular Leak Is Dependent on the Endothelial Protein C Receptor

J. Griffin, W. Ruf, A. von Drygalski, 2013, Arteriosclerosis, thrombosis, and vascular biology.

Structure-activity studies of CTL inhibitory peptides derived from HLA class I molecules

J. Griffin, A. Krensky, C. Clayberger, 1997 .

Assembly and expression of an intrinsic factor IX activator complex on the surface of cultured human endothelial cells.

J. Griffin, P. Hopmeier, R. Schleef, 1992, The Journal of biological chemistry.